Tandem Diabetes Care (TNDM) Getting Somewhat Favorable Press Coverage, Analysis Finds
Headlines about Tandem Diabetes Care (NASDAQ:TNDM) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tandem Diabetes Care earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 46.507104283311 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s rankings:
- Tandem Diabetes Care (TNDM) Upgraded to “Buy” at Zacks Investment Research (americanbankingnews.com)
- Zacks: Brokerages Anticipate Tandem Diabetes Care Inc (TNDM) Will Announce Quarterly Sales of $34.36 Million (americanbankingnews.com)
- Tandem Diabetes Care Announces Retirement of CFO and … – Business Wire (press release) (businesswire.com)
- Tandem Diabetes Care Announces Retirement of CFO and Successor Appointment (finance.yahoo.com)
- -$1.30 Earnings Per Share Expected for Tandem Diabetes Care Inc (TNDM) This Quarter (americanbankingnews.com)
A number of research firms have weighed in on TNDM. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a report on Wednesday. Robert W. Baird restated a “hold” rating and set a $3.00 target price on shares of Tandem Diabetes Care in a report on Sunday, November 19th. Piper Jaffray Companies restated a “hold” rating and set a $15.00 target price on shares of Tandem Diabetes Care in a report on Friday, October 6th. Finally, Wedbush reiterated an “outperform” rating and set a $17.00 price objective (down previously from $50.00) on shares of Tandem Diabetes Care in a report on Tuesday, October 10th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $11.29.
Shares of Tandem Diabetes Care (NASDAQ:TNDM) remained flat at $$2.40 on Friday. 144,815 shares of the company’s stock traded hands, compared to its average volume of 324,468. Tandem Diabetes Care has a 1-year low of $2.15 and a 1-year high of $30.00. The company has a current ratio of 1.90, a quick ratio of 0.88 and a debt-to-equity ratio of -2.70.
Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, October 26th. The medical device company reported ($3.09) EPS for the quarter, beating the consensus estimate of ($3.74) by $0.65. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 79.45%. The firm had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.92 million. During the same quarter in the prior year, the business posted ($0.97) EPS. The business’s revenue for the quarter was up 119.7% compared to the same quarter last year. sell-side analysts expect that Tandem Diabetes Care will post -15.37 earnings per share for the current year.
In other news, CEO Kim D. Blickenstaff bought 285,700 shares of the business’s stock in a transaction that occurred on Friday, October 13th. The shares were purchased at an average cost of $3.50 per share, with a total value of $999,950.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 20.90% of the stock is owned by corporate insiders.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.